+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bladder Cancer Drugs Market Research Reports

From
Urinary Tract Cancer (Oncology) - Drugs in Development, 2021 - Product Thumbnail Image

Urinary Tract Cancer (Oncology) - Drugs in Development, 2021

  • Report
  • April 2021
  • 35 Pages
  • Global
From
From
From
From
2020 Methotrexate Test Volume and Sales Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations - Product Thumbnail Image

2020 Methotrexate Test Volume and Sales Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations

  • Report
  • February 2020
  • Japan, United States, ... Japan, United States, Europe
From
Global Doxorubicin Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Doxorubicin Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 140 Pages
  • Global
From
From
From
Loading Indicator

The Bladder Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat bladder cancer. Bladder cancer is a type of cancer that affects the urinary tract and is the sixth most common type of cancer in the United States. Common treatments for bladder cancer include chemotherapy, radiation therapy, and surgery. Drugs used to treat bladder cancer are typically classified as either targeted therapies or immunotherapies. Targeted therapies are designed to target specific molecules or pathways in the body that are involved in the growth and spread of cancer cells. Immunotherapies are designed to stimulate the body’s own immune system to fight cancer cells. Some of the major companies in the Bladder Cancer Drugs market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development and sale of drugs used to treat bladder cancer. Show Less Read more